AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03315130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection
Study NCT03079310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
Study NCT03977233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
Study NCT03977233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
Study NCT03977233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: 180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
Study NCT03977233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
Study NCT03887780 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto,Bay 59-7939)
Description: 15 mg and 20 mg (OD)
Study NCT03537014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy performed by therapist team
Study NCT03537014 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy performed by therapist team
Study NCT03537014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midomafetamine HCl
Description: Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions
Study NCT03537014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo during three experimental sessions
Study NCT01330602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPRESS intervention
Description: The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy
Study NCT03790670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Study NCT02526368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given IV
Study NCT02526368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C,15N2-urea
Description: Given IV
Study NCT02526368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT01782625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO exercise at depth
Description: Subjects will NOT exercise while at depth
Study NCT01782625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise at depth
Description: Subjects will exercise while at depth
Study NCT02300038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (Xylocaine)
Description: perineuromally administration of 1 ml lidocaine
Study NCT02300038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine (Xylocaine)
Description: perineuromally administration of 1 ml lidocaine
Study NCT04195399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04195399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04195399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04195399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04195399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Given PO
Study NCT04195399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04195399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04195399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT02300038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: perineuromally administration of NaCL
Study NCT02300038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: perineuromally administration of NaCL
Study NCT04292262 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT00650325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride Tablets 100 mg
Description: 100mg, single dose fasting
Study NCT00650325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® Tablets 100 mg
Description: 100mg, single dose fasting
Study NCT03566914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: Tadalafil 10 mg per oral once daily for 3 months
Study NCT03566914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TPlacebo tablet per oral once daily for 3 months
Study NCT00474045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study NCT00474045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6
Study NCT02073097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV (375mg/m\^2)
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV (750mg/m\^2)
Study NCT00474045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study NCT00474045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study NCT02219789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Given IV (50mg/m\^2)
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate
Description: Given IV (1.4mg/m\^2)
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO (100mg)
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
Study NCT02073097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: PO (400mg)
Study NCT02219789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT02219789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03291522 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided rete testis flushing and aspiration
Description: Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
Study NCT01058993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100 or plerixafor
Description: The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
Study NCT01470625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LCP Program
Description: The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Oxaliplatin
Description: 140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 900-1750 mg/m\^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Day 1 of 21 day cycle.
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 250-500mg/m\^2 and Maintenance dose of 125-250 mg/m\^2 by vein on Day 1 of 21 day cycle.
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 300-400 mg/m\^2 bolus + 600-1000 mg/m\^2 infusion over 22 hours on Days 1-2 of each cycle.
Study NCT00941499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
Study NCT02438826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Description: Administered SC
Study NCT02438826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galcanezumab 300 mg
Description: Administered SC
Study NCT02438826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04486053 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: The patients who agreed to participate to the study were assessed with a survey which included age, gender, height, weight and hand dominancy questions. Sensory, motor and functional assessments of the bilateral hand were performed.
Study NCT04437368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005; Low Dose
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
Study NCT04437368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005; High Dose
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
Study NCT04437368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005; Low Dose
Description: Part 2 of the study will test one dose: Low Dose.
Study NCT01546467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
Study NCT00965926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study NCT00385411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate microgranules
Description: 20 to 30 mg/kg/day
Study NCT01995539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapy regimen
Description: Subjects will be recommend changes in therapy regimens.
Study NCT05271058 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: 23 eyes that didn't receive any intraoperative steroids
Study NCT05271058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone group
Description: 23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
Study NCT05271058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (TA) group
Description: 23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
Study NCT04274270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
Study NCT00889057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg bid until progression or inacceptable toxicity
Study NCT02368106 — intervention group
Intervention type: RADIATION
Intervention: Radiation Therapy
Description: targeted radiation treatment
Study NCT03046615 — intervention group
Intervention type: DEVICE
Intervention: EEG Electrode Patch
Description: The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
Study NCT03046615 — intervention group
Intervention type: DEVICE
Intervention: Standard Needles
Description: Needles are placed in the muscles surrounding the eye to measure eye movements.
Study NCT04563650 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
Study NCT04563650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
Study NCT01719107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938 chewable tablets
Description: 2 chewable tablets with breakfast for 4 weeks
Study NCT01719107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewable tablets
Description: 2 chewable tablets with breakfast for 4 weeks
Study NCT01885728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: An arginine rich nutritional supplement
Description: Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
Study NCT01308606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC capsule
Description: Single intake of one 150-mg capsule without food
Study NCT01308606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC or gelatin capsule
Description: Single intake of one 150-mg capsule after high-fat breakfast
Study NCT01308606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC or gelatin capsule
Description: Single intake of one 150-mg capsule without food
Study NCT01308606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC or gelatin capsule
Description: Single intake of one 150-mg capsule after standardized breakfast
Study NCT01308606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 gelatin capsule
Description: Single intake of one 150-mg capsule without food
Study NCT01720732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifeline NET
Description: Short Version of Narrative Exposure Therapy
Study NCT01936896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha 1-Antitrypsin
Study NCT02309437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Use oxycodone to treat patients with mild pain caused by radiation mucositis.
Study NCT02309437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
Study NCT04007458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter
Description: MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
Study NCT04007458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Phone Call
Description: Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
Study NCT03771014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobility
Description: This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
Study NCT03725540 — intervention group
Intervention type: DEVICE
Intervention: I-gel
Description: Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
Study NCT03725540 — intervention group
Intervention type: DEVICE
Intervention: Baska_mask
Description: Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
Study NCT01704625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
Study NCT01704625 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic Manipulative Treatment
Description: The sham group will receive 3 sham treatments.
Study NCT04190628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-1310
Description: Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
Study NCT04190628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules.
Study NCT02042079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EFTR with LA
Description: (Endoscopic full-thickness resection with laparoscopic assistance)
Study NCT04547088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Anti-PD-1 targeted immunotherapy
Study NCT04547088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor